(241) Development of subcutaneous In Situ gelling formulation of anti-PD-L1 peptide for cancer treatment
Introduction: The FDA has approved monoclonal antibodies for cancer therapy, all administered via IV infusion. To overcome the limitations of IV infusion, companies are developing subcutaneous formulations. Recently, the FDA approved the first subcutaneous monoclonal antibody. However, high molecular weight of antibody presents challenges, such as aggregation and increased viscosity, due to the need for high concentrations within limited injection volumes. In this study, we are developing a subcutaneous formulation of an anti-PD-L1 peptide, which, due to its smaller size, may help address these challenges.
Learning Objectives:
understand the potential of PLGA-PEG-PLGA copolymer for sustained release gel formulation.
understand the significance of peptides over monoclonal antibodies for subcutaneous formulation.
